Rheumatoid arthritis is characterised by infiltration of activated immunocompetent cells into synovial tissues. Activated macrophages, secreting proinflammatory cytokines, are found in rheumatoid arthritis synovitis in the presence of memory T cells, which are apparently not producing detectable quantities of those cytokines usually associated with monocyte activation.
Rheumatoid arthritis is clinically characterised by pain, stiffness and synovitis, with overproduction of synovial fluid. Chronic disease causes cartilage and bone destruction, and the resultant morbidity. Despite the fact that these features were first described nearly 150 years ago, [1] the mechanisms that initiate and perpetuate this inflammatory disease remain poorly characterised. However, increased understanding of the pathology of rheumatoid arthritis and the mechanisms of immune system activation suggests that the family of haemopoietic growth factors that are usually associated with maturation of bone marrow precursors might be involved.
This family includes: • interleukin (IL)-3 • granulocyte colony-stimulating factor (G-CSF) • macrophage colony-stimulating factor (M-CSF) • granulocyte-macrophage colony-stimulating factor (GM-CSF).
However, neither IL-3 protein nor its messenger RNA (mRNA) can be detected in the rheumatoid joint,(2) so discussion will be limited to the potential role of CSFs in development and maintenance of the local disease process in rheumatoid arthritis synovitis.
Immunopathogenesis of Rheumatoid Arthritis
Examination of inflamed synovium in rheumatoid arthritis demonstrates increased vascularity, with infiltration of the normal relatively acellular synovial membrane with macrophages, T cells and plasma cells)3) The localisation of the CD4+ T cells into aggregates surrounded by macrophages has led to comparisons being drawn between rheumatoid arthritis synovitis and lymph nodes, with the implication that immune activation is ongoing in these inflamed joints. Cell surface expression of the following markers is increased:
• major histocompatibility complex (MHC) class II antigens on vascular endothelial cells and infiltrating cells [4] • adhesion molecules such as intercellular adhesion molecule (ICAM)-l, 2 and 3 on monocyte-derived lining layer cells, [S] and lymphocyte function associated antigen (LFA)-l on infiltrating lymphocytes. [6] This suggests that antigen processing and presentation by macrophages could be occurring in rheumatoid arthritis synovitis. The CD4+ T cells express the CD45Ro antigen [7] which, together with the paucity of immature B cells, implies that an immune reaction has occurred in synovial tissue, with subsequent activation of immature T cells into their memory form, and those of the B lineage into (auto)-antibody-producing plasma cells.
In this environment it would be usual to find cytokines associated with macrophage and T cell activation. Indeed, macrophage-derived cytokines such as IL-l, IL-6 and tumour necrosis factor-a. (TNFa.) are usually detected in rheumatoid arthritis synovial tissues,f8-10] However, the cytokines usually associated with macrophage and T cell activation, such as interferon-y (lFNy),[ll] IL-2 [2] and lymphotoxin (TNFP), [12] have not been readily detected, although small quantities of their mRNAs have been found. [l 3] However, no IL-4, [14] IL-5 or IL_7, [15] nor their mRNAs, have been found in rheumatoid arthritis synovial tissues. This implies that macrophage activation seems to be occurring in the unusual circumstances of minimal, if any, stimuli from the T helper 1 (T H 1) or T H2 subsets of T cells.
Potential Role of Colony-Stimulating Factors
The difficulty in detection of IFNy, which is widely regarded as the most potent mediator of human leucocyte antigen (HLA)-DR expression, [16] has led to a search for other cytokines to explain this feature of rheumatoid arthritis synovitis. The second most potent stimulator of HLA-DR expression is GM-CSF, [17] which is one ofa variety ofCSFs © Adis International Limited . All rights reserved. GM-CSF is synthesised by macrophages derived from rheumatoid arthritis synovial tissue, [19] and can act on rheumatoid arthritis monocytes to induce MHC class II expression,l20] This suggests that it is also physiologically active in this disorder as a result of autologous stimulation. In addition, GM-CSF increases expression of monocyte adhesion molecules, [21] another feature of rheumatoid arthritis synovitis. Therefore, significant practical and theoretical evidence exists implicating GM -CSF in the initiation of local antigen presentation and synovial inflammation. This is supported by the observation that patients receiving GM-CSF after chemotherapy, [22] or for the neutropenia of Felty's syndrome,[23] developed flares of their arthritis.
As for the other CSFs, Williamson et al,l24] detected in rheumatoid arthritis synovial fluid an activity stimulating WEHI-3B(D+) cells, suggesting that G-CSF is also present. G-CSF acti vates cells of the granulocyte lineage, particularly neutrophils, of which up to 1 0 lllL are found in synovial fluid from patients with rheumatoid arthritis. G-CSF is also produced by monocytes, [25] and data from patients receiving treatment with G-CSF for neutropenias shows that it can stimulate bone marrow production of neutrophil precursors, [26] and enhance their movement from blood vessels into extravascular tissues such as synovial fluid. G-CSF activates neutrophils by increasing expression of receptors for complement (C3bi)[27] and immunoglobulin (FcyRI), [28] thereby increasing their ability to bind immune complexes, and activates the processes involved in phagocytosis.
[29] G-CSF also enhances production of superoxide in response to exogenous stimuli, [30] suggesting that it can also prime neutrophils to induce tissue damage. The presence of activated neutrophils expressing some of these receptors and producing inflammatory mediators such as prostaglandins, leukotrienes and superoxide in rheumatoid arthritis synovial fluid suggests that G-CSF may well be important in this process. However, GM-CSF also improves circulating neutrophil counts in neutropenic patients, [31] causes neutrophils to degranulate, [32] and increases their production of oxygen radicals as well as enhancing their ability to produce leukotrienes [33] and IL-l and TNFaJ34] Therefore, in inflammatory disease, G-CSF may not be exerting these effects on neutrophils in isolation.
M-CSF is a glycosylated homodimeric protein usually associated with maturation and development of monocyte/macrophage colonies. It has been detected in rheumatoid arthritis synovitis, [2] and has been implicated in the process of monocyte activation in this disease. M-CSF increases the ability of mature monocytes to migrate to the extravascular space, [35] and enhances antibody-mediated cytotoxicity)36] In addition, M-CSF primes monocytes to produce TNFa in response to second stimuli, and directly induces production of interferon [37] and G-CSF.!38J
Role of Tumour Necrosis Factor-a
Analytical data from measurement of cytokines in synovial fluid from rheumatoid arthritis patients suggests that those from the macrophage lineage predominate.!39] Of these, TNFa appears to be a pivotal molecule in pathophysiology. This is partly because it is found in rheumatoid arthritis synovial membrane, but also because it is detected at the junction between cartilage and overlying pannus, [9] where it could induce collagenase and destroy underlying cartilage. In addition, antibodies against TNFa, but not those against lymphotoxin, reduce production of IL-l from cultures in vitro of extracted synovial cells, [40] suggesting that TNFa may be important in control of pro-inflammatory cytokine production. Furthermore, mice transgenic for the human TNFa gene develop joint disease similar to rheumatoid arthritis, implying that uncontrolled production of TNFa can induce disease. [41] Studies in patients with rheumatoid arthritis have demonstrated that a chimeric antibody (cA2), which binds to soluble and cell-associated TNFa, can suppress both synovitis and acute phase response, albeit only temporarily. [42] Therefore, not only is TNFa involved in the disease process, but its importance is confirmed by the demonstration that it is a therapeutic target in rheumatoid arthritis.
Control of Cytokine Production
The process that initiates TNFa production in rheumatoid arthritis remains unclarified. However, substantial evidence suggests that CSFs may be involved in stimulation of cytokine production from monocytes. GM-CSF induces production of mRNA for TNFa from monocyte-derived cell lines, [43] and stimulates production of mRNA for IL-I P from human monocytes [44] and neutrophils. [45] Mice transgenic for the GM-CSF gene have elevated levels of circulating IL-l, [46] presumably as an result of overexpression of the transgene. In addition, GM -CSF has been reported to increase production of pro-inflammatory cytokines from human monocytes in cuiture. [47] However, 2 further studies failed to detect TN Fa protein in culture supernatants after stimulation of monocytes with GM-CSF alone,!44.48] but did show an increase in TNFa mRNA production.!48] Similarly, M-CSF failed to stimulate biologically active TNFa, but in this instance no increase in TNFa mRNA was observed.f 491 These conflicting data could be because soluble inhibitors also produced during stimulation interfered with the assay system, [45] or because cell-associated cytokines were produced that are undetectable by soluble assays. [44] Nevertheless, the addition of IFNy to GM-CSFstimulated monocytes did lead to enhanced production of both TNFa and IL_l. [44, 48] Therefore, in rheumatoid arthritis, the presence of GM-CSF could prime monocytes by allowing increased production of the mRNAs for pro-inflammatory cytokines, which can be translated into protein following an as yet unidentified second stimulus.
Colony Stimulating Factor Localisation in Rheumatoid Arthritis
GM-CSF production by rheumatoid arthritis synovial cells, in common with that of other macrophage-derived cytokines, is induced by the ubiquitously present TNFa.!19] Furthermore, antibodies against TN Fa reduce GM-CSF production in vitro. !50] However, the exact nature of which cell is producing the GM-CSF, and is subject to control in these synovial cell cultures, cannot be characterised by this in vitro technique. The only way in which such information can be obtained for CSFs in rheumatoid arthritis is by localising each molecule in the context of rheumatoid arthritis synovitis. This provides an in vivo snapshot of the pathology, helping to relate synovial structure with cytokine function , thereby allowing associations to be considered.
At present, data are limited solely to GM-CSF. Using rabbit polyclonal antisera, the presence of GM-CSF and other macrophage-derived cytokines at the destructive cartilage/pannus junction has been demonstrated. 1511 This confirms that GM-CSF is probably made by cells from the monocyte lineage which characteristically infiltrate this site.l l91 Furthermore, if indeed cartilage is the site for chronic antigen production that perpetuates the synovitis in rheumatoid arthritis, then the presence at this site of GM-CSF, with its ability to upregulate MHC class II and adhesion molecules for antigen presentation, could be relevant to disease pathogenesis.
More detailed examination of rheumatoid arthritis synovium using monoclonal antibodies l521 has shown that the synovial lining layer also contains GM-CSF, suggesting that macrophages at this site could provide a potential source for GM-CSF secretion into synovial fluid.
Macrophages are not the only source of GM-CSF. Its production by endothelial cells can also be stimulated,1 53 1 and this appears to be another relevant source of GM-CSF in rheumatoid arthritis synovitis. Up to 50% of blood vessel endothelial cells in synovial membrane from patients with rheumatoid arthritis stained with the anti-GM-CSF monoclonal antibody, whereas it was not localised to any blood vessels in synovium from patients with osteoarthritis.1521 It is therefore possible that at this site GM-CSF could exert an effect on circulating monocytes and granulocytes as they move from the vascular compartment to the synovial milieu. The suggestion that stimulation of endothelial cells by cytokines also results in G-CSF production[541 implies that granulocytes could be activated in a similar manner.
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Receptors for Colony-Stimulating Factors

Field
No analysis of any cytokine can be viewed in isolation from that of its receptor. Again, for the CSFs in rheumatoid arthritis, information is limited to the GM-CSF receptor. Increased numbers of circulating monocytes express the GM-CSF receptor in rheumatoid arthritis patients when compared with healthy controls,!551 implying that monocytes from patients with rheumatoid arthritis are potentially more susceptible to the actions of GM-CSF. When taken in association with the immunohistochemical data, this suggests that, in rheumatoid arthritis, interactions between endothelial cellderived GM-CSF and its receptor on monocytes could be an important mechanism of activation during migration of monocytes into synovial tissue, where they become tissue macrophages.
The interrelationships between the other CSFs and their receptors in autoimmune disease remains unknown, but the control of the murine M-CSF receptor expressi,pn by GM-CSF,! 56 1 albeit in a negative manner, indicates that neither the CSFs nor their receptors should be considered in isolation.
Implications for Drug Therapy
The slow acting (or 'disease-modifying') antirheumatic drugs (DMARDs) remain standard therapy for rheumatoid arthritis. Many of them have the adverse effect of bone marrow suppression,1571 as do the cytotoxic immunosuppressive agents.l 581 The mechanism of this adverse reaction is interference with the effects of CSFs on bone marrow precursors,! 59 1 raising the possibility that the same mechanism may be involved in the therapeutic actions of DMARDs.
However, histological data suggest that there are changes in the synovial tissue after treatment with DMARDs, which might also imply a local action. Therapy with gold salt results in a reduction in numbers of infiltrating synovial macrophages, as well as a decrease in the number of cells staining for pro-inflammatory cytokines.l 601 Therefore, DMARDs may act by interfering with monocyte activation 
Adhesion molecule expression Fig. 1 . Colony-stimulating factors (CSFs) made by endothelial cells may be involved in macrophage activation as they enter the synovial membrane, become activated and secrete pro-inflammatory cytokines and subsequently stimulate B cells into plasma cells. As they mature they move to the lining layer where they manufacture pro-inflammatory cytokines and secrete them into synovial fluid. Neutrophils could also become activated in this way, passing directly through the membrane into the synovial fluid. In this scenario, T cells fail to produce cytokines upon entry into the membrane and pass through into the synovial fluid without significant change. Abbreviations: G-CSF = granulocyte CSF; GM-CSF = granulocyte-macrophage CSF; IL= interteukin; M-CSF = macrophage CSF; MHC = major histocompatibility complex; TGF = transforming growth factor; TNF = tumour necrosis factor.
during movement between the intra-and extra-vascular compartments. Interestingly, endothelial cell proliferation is reduced after exposure to gold, [61] sulfasalazine [62] and other similar drugs. Therefore, as well as the postulated effects on bone marrow production, [63] it is intriguing to speculate that the alteration in endothelial cell function resulting from DMARD action may influence their ability to produce GM-CSF and G-CSF, thereby preventing monocyte activation upon entry into synovial tissue.
Conclusions
Considerable theoretical data are now available to imply a role for CSFs in the pathophysiology of rheumatoid arthritis. Substantial evidence is accu-mulating that GM-CSF is directly involved in initiation of neutrophil and monocyte activation and cytokine production in this disease, as summarised in figure 1. It remains to be seen whether further evidence for the involvement of the other CSFs is forthcoming . However, in the future these factors or their receptors could become a new therapeutic target for neutralising antibodies or for molecules that block CSF receptors without initiating signal transduction. 
